Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02225184 · ClinicalTrials.gov registry record
Impact of Delta Opioid Receptor Gene (OPRD1) Variations on Treatment Outcome in African Americans
A clinical trial of Genetic Underpinning of Substance Abuse and Polymorphism-genetic, sponsored by National Institute on Drug Abuse (NIDA).
- Completed
- Registry status
- 81
- Enrollment target
- 1
- Study location
NCT02225184: Completed study of Genetic Underpinning of Substance Abuse and Polymorphism-genetic, sponsored by National Institute on Drug Abuse (NIDA).
NCT02225184 is a study of Genetic Underpinning of Substance Abuse and Polymorphism-genetic that has completed, run by National Institute on Drug Abuse (NIDA). The registered enrollment target is 81 participants. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02225184, a study of Genetic Underpinning of Substance Abuse and Polymorphism-genetic, has completed, sponsored by National Institute on Drug Abuse (NIDA).
- COMPLETED
- Registry status
- 81 participants
- Enrollment target
- 1
- Study location
Study Summary
Background: \- Differences in peoples genes can make them respond to drugs in different ways. Methadone and buprenorphine are two drugs used to treat drug addiction. A study showed that African Americans with a certain genetic marker did better using one kind of drug treatment over the other. Researchers want to see if they can repeat these findings. They also want to study other things that affect how well people do in treatment. Objective: \- To see if certain genetic markers and other facts about a person s life can predict how well they do in treatment for addiction to opioids and cocaine. Eligibility: \- African American adults age 18 and over. They must be former or current participants in an Archway Treatment Clinic study. They must have been on a stable dose of either study drug for at least 12 weeks. They also must have given urine samples regularly for at least 10 weeks. Design: * Participants will come to the clinic for 1 visit lasting about 2 hours. * Participants will give 1 teaspoon of blood for genetic testing. They will be asked if their sample can be used in future studies. * If researchers cannot get enough blood, they will do a cheek swab. This will collect skin cells for genetic testing. * Participants will fill out 3 questionnaires. * Results of genetic testing and answers to questionnaires will be kept private.
Conditions Studied
Study Locations (1)
Maryland
- National Institute on Drug Abuse - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 81 participants |
| Start Date | 2014-08-23 |
| Est. Completion | 2018-12-31 |
What the finished NCT02225184 record still lists
NCT02225184 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 81 participants, a relatively small participant target.
The record links to 4 conditions, with Genetic Underpinning of Substance Abuse appearing as the primary indexed condition, and to 0 interventions.
NCT02225184 reports a single indexed study location in Maryland.
Frequently Asked Questions
What is clinical trial NCT02225184 about?
NCT02225184 is a clinical study titled "Impact of Delta Opioid Receptor Gene (OPRD1) Variations on Treatment Outcome in African Americans". Background: \- Differences in peoples genes can make them respond to drugs in different ways. Methadone and buprenorphine are two drugs used to treat drug addiction. A study showed that African Americans with a certain genetic marker did better using one kind of drug treatment over the other. Resea...
What is the current status of trial NCT02225184?
This trial is currently completed. The enrollment target is 81 participants. The study started on 2014-08-23. Estimated completion is 2018-12-31.
What conditions does trial NCT02225184 study?
This clinical trial studies the following conditions: Genetic Underpinning of Substance Abuse, Polymorphism-genetic, Drug Abuse/Dependence, Opiod-Related Disorders.
Who is sponsoring clinical trial NCT02225184?
This trial is sponsored by National Institute on Drug Abuse (NIDA), which has 335 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02225184 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04966481 · 81 participants · Phase 3
Palbociclib and Cetuximab Versus Cetuximab Monotherapy for Patients With CDKN2A-altered, HPV-unrelated Head and Neck Squamous Cell Carcinoma Who Experienced Disease Progression on a PD-1/L1 Inhibitor
- NCT05109429 · 81 participants · NA
Developing a Clinical Outcome Assessment for Opioid Craving
- NCT05112601 · 81 participants · Phase 2
Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma
- NCT05305911 · 81 participants · Phase 2
Sodium Glucose Co-Transporter 2 (SGLT2) and STEMI
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI